Felzartamab AMR
2024
Felzartamab in Chronic Active Antibody-Mediated Rejection
In 22 kidney-transplant recipients with chronic active antibody-mediated rejection, felzartamab resolved rejection morphology more often than placebo.
Result
- Absolute difference
- 62 points
- NNT
- 2
difference6295% CI 19-100
Absolute difference and NNT are derived from the event rates.
Also reported: Resolution of AMR at wk 24: risk ratio 0.23 (95% CI 0.06 to 0.83). Recurrent AMR observed during follow-up.
- Subtopic
- Antibody-mediated rejection
- Design
- Phase 2 RCT
- Relevance
- Supporting: context rather than must-know.
- Source
- Mayer KA, et al. N Engl J Med. 2024;391(2):122-132.doi 10.1056/NEJMoa2400763
Discussion & critique
First evidence-based option in chronic active AMR, but a very small sample; phase 3 is awaited.